Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development
Alice Egerton, Anthony A. Grace, James Stone, et al.
Schizophrenia Research (2020) Vol. 223, pp. 59-70
Open Access | Times Cited: 83

Showing 26-50 of 83 citing articles:

Probing the biological consequences of a previously undescribed de novo mutation of ZMYND11 in a schizophrenia patient by CRISPR genome editing and induced pluripotent stem cell based in vitro disease-modeling
Csongor Tordai, Edit Hathy, Hella Gyergyák, et al.
Schizophrenia Research (2024)
Open Access | Times Cited: 2
The impact of spectral basis set composition on estimated levels of cingulate glutamate and its associations with different personality traits
Verena F. Demler, Elisabeth Sterner, Martin Wilson, et al.
BMC Psychiatry (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Importance of good hosting: reviewing the bi-directionality of the microbiome-gut-brain-axis
Carolina F. F. A. Costa, Joana Ferreira‐Gomes, Fernando Barbosa, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 2
Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?
Ariel Frajerman, Linda Scoriels, Oussama Kébir, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 13, pp. 6881-6881
Open Access | Times Cited: 16
Ketamine as a pharmacological tool for the preclinical study of memory deficit in schizophrenia
José Eduardo Suárez Santiago, Gabriel Roldán, Ofir Picazo
Behavioural Pharmacology (2022) Vol. 34, Iss. 2-3, pp. 80-91
Closed Access | Times Cited: 12
Blood Glutamate Scavenging With Pyruvate as a Novel Preventative and Therapeutic Approach for Depressive-Like Behavior Following Traumatic Brain Injury in a Rat Model
Dmitry Frank, Benjamin F. Gruenbaum, Ilan Shelef, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 11
Real‐world effectiveness of mood stabilizer use in schizophrenia
Arto Puranen, Marjaana Koponen, Markku Lähteenvuo, et al.
Acta Psychiatrica Scandinavica (2022) Vol. 147, Iss. 3, pp. 257-266
Open Access | Times Cited: 11
Paeonol, the active component of Cynanchum paniculatum, ameliorated schizophrenia-like behaviors by regulating the PI3K-Akt-GSK3β-NF-κB signalling pathway in MK-801-treated mice
Ho Jung Bae, Jae Youn Kim, Seung‐Hyuk Choi, et al.
Journal of Ethnopharmacology (2023) Vol. 314, pp. 116627-116627
Closed Access | Times Cited: 6
The association between peripheral inflammation, brain glutamate and antipsychotic response in Schizophrenia: Data from the STRATA collaboration
Sunniva Fenn‐Moltu, J.F.W. Deakin, Richard Drake, et al.
Brain Behavior and Immunity (2023) Vol. 111, pp. 343-351
Open Access | Times Cited: 6
Synergistic, long-term effects of glutamate dehydrogenase 1 deficiency and mild stress on cognitive function and mPFC gene and miRNA expression
Kfir Asraf, Hiba Zaidan, Baylasan Natoor, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Mismatch negativity in schizophrenia spectrum and bipolar disorders: Group and sex differences and associations with symptom severity
Atle Bråthen Pentz, Clara Maria Fides Timpe, E Normann, et al.
Schizophrenia Research (2023) Vol. 261, pp. 80-93
Open Access | Times Cited: 6
A Metabolomics Study of Serum in Hospitalized Patients With Chronic Schizophrenia
Naomichi Okamoto, Atsuko Ikenouchi, Keita Watanabe, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 15
The cortical hypogyrification pattern in antipsychotic-naive first-episode schizophrenia
Xin Gao, Yao Li, Fei Li, et al.
Cerebral Cortex (2023) Vol. 33, Iss. 12, pp. 7619-7626
Closed Access | Times Cited: 5
Genes implicated by a methylome-wide schizophrenia study in neonatal blood show differential expression in adult brain samples
Edwin J. C. G. van den Oord, Lin Xie, Min Zhao, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 5, pp. 2088-2094
Closed Access | Times Cited: 5
Etiopathogenic Models of Psychosis Spectrum Illnesses Must Resolve Four Key Features
Sophia Vinogradov, Arif Hamid, A. David Redish
Biological Psychiatry (2022) Vol. 92, Iss. 6, pp. 514-522
Open Access | Times Cited: 8
NMDA glutamate receptor antagonist MK‐801 induces proteome changes in adult human brain slices which are partially counteracted by haloperidol and clozapine
Valéria de Almeida, Niele Dias Mendes, Giuliana S. Zuccoli, et al.
Journal of Neurochemistry (2024) Vol. 168, Iss. 3, pp. 238-250
Closed Access | Times Cited: 1
Endocannabinoid levels in plasma and neurotransmitters in the brain: a preliminary report on patients with a psychotic disorder and healthy individuals
Carmen F.M. van Hooijdonk, Michiel G.J. Balvers, Marieke van der Pluijm, et al.
Psychological Medicine (2024) Vol. 54, Iss. 9, pp. 2189-2199
Open Access | Times Cited: 1
Defining the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences
J.F.W. Deakin, Elizabeth B. Liddle, Mohanbabu Rathnaiah, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Potassium channel modulators and schizophrenia: an overview of investigational drugs
Meghan Musselman, Eric Huynh, Rachana Kelshikar, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 6, pp. 471-477
Closed Access | Times Cited: 4
Shedding light on the role of CX3CR1 in the pathogenesis of schizophrenia
Katarzyna Chamera, Magdalena Szuster-Głuszczak, Agnieszka Basta‐Kaim
Pharmacological Reports (2021) Vol. 73, Iss. 4, pp. 1063-1078
Open Access | Times Cited: 8
Modulation of mGlu5 improves sensorimotor gating deficits in rats neonatally treated with quinpirole through changes in dopamine D2 signaling
Russell W. Brown, Christopher G. Varnum, Liza J. Wills, et al.
Pharmacology Biochemistry and Behavior (2021) Vol. 211, pp. 173292-173292
Open Access | Times Cited: 7
Metabolomics study based on GC–MS reveals a protective function of luteolin against glutamate‐induced PC12 cell injury
Ying Gao, Jinfeng Zhu, Mengyao Sun, et al.
Biomedical Chromatography (2022) Vol. 37, Iss. 2
Closed Access | Times Cited: 5
A Review of Glutamate and Its Receptors: Their Roles in Brain Physiology and Pathology
Sevgi Uğur Mutluay, Hülya Karataş
Acta Medica (2022) Vol. 53, Iss. 2, pp. 99-109
Open Access | Times Cited: 4
Correlations between biochemical and clinical parameters in patients at risk for schizophrenia spectrum disorders
О. К. Савушкина, И. С. Бокша, M. A. Оmelchenkо, et al.
Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) (2023), Iss. 3, pp. 213-224
Closed Access | Times Cited: 2
Non-linear variations in glutamate dynamics during a cognitive task engagement in schizophrenia
James W.C. Graham, Peter Jeon, Jean Théberge, et al.
Psychiatry Research Neuroimaging (2023) Vol. 332, pp. 111640-111640
Closed Access | Times Cited: 2

Scroll to top